
News|Articles|May 1, 2002
Methylphenidate-MAOI contraindication.
New contraindications and precautions have been added to the labeling of methylphenidate HCl tablets (Ritalin and Ritalin-SR, Novartis)-approved for treatment of attention deficit/hyperactivity disorder (ADHD).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
Cancer survival fell and deaths rose during first two years of COVID-19
3
PBM reform. It has finally happened
4
TrumpRx launches; some experts question its long-term value
5

























